Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-005829-88
    Sponsor's Protocol Code Number:AH0003
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-04-28
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2020-005829-88
    A.3Full title of the trial
    A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer’s Disease (AD), Followed by an Open-Label Extension Period
    Étude en double-aveugle (patient et investigateur), contrôlée contre placebo, visant à évaluer l’efficacité, la sécurité d’emploi et la tolérance du bépranémab (UCB0107) chez des patients atteints de la maladie d’Alzheimer (MA) au stade prodromal à léger, suivie d’une phase d’extension en ouvert
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to test the efficacy, safety, and tolerability of bepranemab (UCB0107) in patients with mild cognitive impairment or mild Alzheimer’s Disease (AD)
    Étude visant à évaluer l’efficacité, la sécurité et la tolérance du bépranémab (UCB0107) chez des patients atteints de troubles cognitifs légers ou de la maladie d’Alzheimer (MA) au stade précoce
    A.4.1Sponsor's protocol code numberAH0003
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUCB Biopharma SRL
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportUCB Biopharma SRL
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUCB BIOSCIENCES GmbH
    B.5.2Functional name of contact pointClin Trial Reg & Results Disclosure
    B.5.3 Address:
    B.5.3.1Street AddressAlfred-Nobel-Strasse 10
    B.5.3.2Town/ cityMonheim
    B.5.3.3Post code40789
    B.5.3.4CountryGermany
    B.5.6E-mailclinicaltrials@ucb.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namebepranemab
    D.3.2Product code UCB0107
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBepranemab
    D.3.9.2Current sponsor codeUCB0107
    D.3.9.3Other descriptive nameUCB0107
    D.3.9.4EV Substance CodeSUB199722
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Alzheimer’s Disease
    Maladie d'Alzheimer
    E.1.1.1Medical condition in easily understood language
    Alzheimer’s Disease
    Maladie d'Alzheimer
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10001896
    E.1.2Term Alzheimer's disease
    E.1.2System Organ Class 100000004852
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    -Investigation of the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer’s Disease (AD)
    -Étude menée contre placebo sur l’effet du bépranémab mesuré par l’Echelle d’évaluation clinique de la démence - sommes des cases (CDR-SB) jusqu’à la Semaine 80 chez des participants à l’étude atteints de la maladie d’Alzheimer (MA) au stade prodromique à léger.
    E.2.2Secondary objectives of the trial
    -Evaluation of the safety and tolerability of bepranemab vs. placebo over 80 weeks in study participants with prodromal or mild Alzheimer’s Disease (AD)
    -Investigation of the effect of bepranemab on tau burden in the brain as measured by [18F]Genentech tau probe 1 (GTP1) positron emission tomography (PET) imaging in study participants with prodromal or mild AD
    -Investigation of the effect of bepranemab vs placebo on cognitive and functional measures over time in study participants with prodromal or mild AD
    -Characterisation of the pharmacokinetic (PK) of bepranemab following repeated intravenous (iv) administration in study participants with prodromal or mild AD
    – Évaluation de la sécurité et de la tolérance du bépranémab contre placebo sur 80 semaines chez des participants à l’étude atteints de la maladie d’Alzheimer (MA) au stade prodromique à léger
    – Étude de l’effet du bépranémab sur la morbidité de la protéine tau dans le cerveau, mesurée par tomographie par émission de positons (TEP) avec le traceur [18F]GTP1 de Genentech ([18F]Genentech tau probe 1) chez des participants à l’étude atteints de la maladie d’Alzheimer (MA) au stade prodromique à léger.
    – Étude contre placebo de l’effet du bépranémab sur la mesure des capacités fonctionnelles et cognitives au fil du temps chez des participants à l’étude atteints de la MA au stade prodromique à léger.
    – Détermination des caractéristiques pharmacocinétiques (PK) du bépranémab après administration intraveineuse (IV) répétée à des participants à l’étude atteints de la MA au stade prodromique à léger.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - 50 to 80 years of age
    - diagnosis of prodromal/mild cognitive impairment (MCI) due to Alzheimer’s Disease (AD) or mild AD according to National Institute of Aging-Alzheimer’s Association (NIA-AA)
    - a global Clinical Dementia Rating (CDR) score of 0.5 to 1.0 and CDR-Memory Box (CDRMB) score ≥0.5 at Screening and Baseline
    - Score of ≤85 for the delayed recall domain of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at Screening
    - Mini-Mental State Examination (MMSE) score ≥20 at Screening
    - Participant has an identified informant that has and will maintain sufficient contact (minimum of 5 hours per week) with the participant to be able to provide accurate information on the participant’s cognitive, functional, and emotional states and of the participant’s personal care
    - At least 6 years of formal education after the age of 5 or work experience to exclude mental deficits other than prodromal or mild AD dementia
    - evidence of cerebral Aβ accumulation by either positive amyloid assessment by either positron emission tomography (PET) scan or cerebrospinal fluid pTau181/Aβ1-42 ratio assessment
    – Patients âgés de 50 à 80 ans
    – Diagnostic de trouble cognitif au stade prodromique à léger causé par la maladie d’Alzheimer (MA) ou de MA au stade léger d’après les critères du NIA-AA (National Institute of Aging-Alzheimer's Association).
    – Score global de 0,5 à 1,0 à l’évaluation clinique de la démence (Échelle CDR) et score ≥ 0,5 à l’évaluation clinique de la démence relative à la mémoire (Échelle CDR-MB) à la sélection et à l’inclusion.
    – Score ≤ 85 pour le domaine de rappel différé avec la batterie de tests RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) à la sélection.
    – Score ≥ 20 au mini-examen de l’état mental (MMSE) à la sélection.
    – Le/la participant(e) a identifié un accompagnateur qui a et maintiendra suffisamment de contact avec lui/elle (au moins 5 heures par semaine) afin de fournir des informations exactes sur l’état cognitif, fonctionnel et émotionnel du/de la participant(e) ainsi que sur ses soins d’hygiène personnelle.
    – Au moins 6 ans d’instruction formelle après l’âge de 5 ans ou expérience professionnelle permettant d’exclure les déficiences intellectuelles autres que la démence liée à la MA de stade prodromique ou léger.
    – Preuves de l’accumulation d’Aβ dans le cerveau par détection positive des plaques amyloïdes par tomographie à émission de positons (TEP) ou évaluation du rapport pTau181/Aβ 1-42 dans le liquide céphalo-rachidien.
    E.4Principal exclusion criteria
    - any evidence of a condition that may affect cognition other than AD
    - contraindications to PET imaging
    - Inability to tolerate or contraindication to magnetic resonance imaging
    - any serious medical condition or abnormality that in the opinion of the investigator would preclude safe participation in and completion of the study or interfere with study assessments and/or study interpretation
    - alcohol or drug abuse within 2 years of screening
    - use of any experimental therapy within the past 6 months (or 5 half lives) prior to screening
    - previous treatment with medication intended to treat a neurodegenerative disorder (other than AD) within 1 year of screening
    - chronic daily treatment with atypical antipsychotics, opiates or opioids, benzodiazepines, barbiturates, hypnotics, or any medication with clinically significant centrally acting antihistamine or anticholinergic activitiy
    - received treatment with monoclonal antibodies (mAbs), cytokines, immunoglobulins, or other blood products within 3 months or 5 half-lives (whichever is longer) prior to first dosing
    – Tout signe probant montrant une affection, autre que la MA, susceptible d’altérer les fonctions cognitives.
    – Contre-indications à l’examen d’imagerie par TEP
    – Incapacité à tolérer l’imagerie par résonance magnétique ou contre-indications
    – Toute affection ou anomalie médicale grave qui, de l’avis de l’investigateur, empêcherait le patient de participer sans risque à l’étude ou de la terminer, ou qui pourrait perturber les évaluations de l’étude et/ou leur interprétation.
    – Consommation abusive d’alcool ou de drogue dans les 2 ans précédant la sélection.
    – Utilisation d’un traitement expérimental au cours des 6 derniers mois (ou 5 demi-vies) précédant la sélection
    – Traitement médicamenteux antérieur visant à traiter un trouble neurodégénératif (autre que la MA) dans l’année précédant la sélection.
    – Traitement chronique quotidien par antipsychotique atypique, opiacé ou opioïde, benzodiazépine, barbiturique, hypnotique ou tout médicament ayant une activité antihistaminique ou anticholinergique centrale cliniquement significative.
    – Traitement par anticorps monoclonaux (Acm), cytokines, immunoglobulines ou autres produits sanguins au cours des 3 mois ou 5 demi-vies précédant la première administration du médicament de l’étude (l’échéance la plus longue prévalant).
    E.5 End points
    E.5.1Primary end point(s)
    1. Change from Baseline to Week 80 in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) total score
    1. Modification du score total de l’échelle CDR-SB d’évaluation clinique de la démence, sommes des cases, entre l’inclusion et la semaine 80
    E.5.1.1Timepoint(s) of evaluation of this end point
    1. From from Baseline to Week 80
    1. De l’inclusion à la Semaine 80
    E.5.2Secondary end point(s)
    1. Incidence of treatment-emergent adverse events (TEAEs)
    2. Incidence of treatment-emergent serious adverse events (TESAEs)
    3. Incidence of TEAEs leading to discontinuation or death
    4. Incidence of Drug-related TEAEs
    5. Change from Baseline in suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
    6. Change from Baseline to Week 56 and Week 80 on indices of tau burden in the brain as measured by [18F]Genentech tau probe 1 (GTP1) positron emission tomography (PET)
    7. Change from Baseline to Week 56 and Week 80 in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14)
    8. Change from Baseline to Week 56 and Week 80 in Amsterdam-Instrumental Activities of Daily Living (A-iADL)
    9. Change from Baseline to Week 56 and Week 80 in Mini-Mental State Examination (MMSE) total score
    10. Serum concentrations of bepranemab over the 80-week Double-blind Treatment Period
    1. Incidence des événements indésirables survenant en cours de traitement (EIt)
    2. Incidence des événements indésirables graves survenant en cours de traitement (EIGt)
    3. Incidence des Eit survenant en cours de traitement menant à l’arrêt du traitement de l’étude ou au décès
    4. Incidence des Eit liés au médicament
    5. Modification depuis l’inclusion des idées et du comportement suicidaires, mesurés par l’échelle d’évaluation de la gravité du risque suicidaire de Columbia (Columbia-Suicide Severity Rating Scale, C-SSRS).
    6. Modification des indices de morbidité de la protéine tau dans le cerveau, mesurée par tomographie par émission de positons (TEP) avec le traceur [18F]GTP1 ([18F]Genentech tau probe 1), entre l’inclusion et la Semaine 56 ou la Semaine 80.
    7. Modification entre l’inclusion et la semaine 56 ou la semaine 80 du score de la sous-échelle cognitive de l’échelle d’évaluation de la maladie d’Alzheimer (ADAS-Cog14).
    8. Modification entre l’inclusion et la semaine 56 ou la semaine 80 du score de l’échelle A-iADL (activités instrumentales de la vie quotidienne d’Amsterdam).
    9. Modification entre l’inclusion et la semaine 56 ou la semaine 80 du score total du MMSE (Mini-Mental State Examination).
    10. Concentrations sériques de bépranémab pendant les 80 semaines de traitement en double insu.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1 - 4: From Baseline to the Safety Follow-Up (Week 152)
    6 - 9: From from Baseline to Week 56 and Week 80
    5 + 10: From from Baseline to Week 80
    1 - 4 : De l’inclusion au suivi de sécurité (Semaine 152)
    6 - 9 : De l’inclusion à la Semaine 56 et la Semaine 80
    5 + 10 : De l’inclusion à la Semaine 80
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability; Immunogenicity
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Double-blind Treatment Period followed by Open-label Extension Treatment Period
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned11
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA65
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    United States
    Belgium
    France
    Germany
    Italy
    Netherlands
    Poland
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Dernière visite du dernier patient
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days25
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days25
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 350
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state58
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 250
    F.4.2.2In the whole clinical trial 450
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-09-28
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-05-27
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:31:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA